Nuvation Bio
NUVB
16 hedge funds and large institutions have $40.9M invested in Nuvation Bio in 2020 Q3 according to their latest regulatory filings, with 16 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
25.49% more ownership
Funds ownership: 0% → 25.49% (+25%)
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$8.64M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
+$8.64M |
| 3 |
6CM
683 Capital Management
New York
|
+$6.48M |
| 4 |
CCA
Castle Creek Arbitrage
Avon,
Colorado
|
+$4.25M |
| 5 |
GC
Greenlight Capital
New York
|
+$3.24M |
Top Sellers
NUVB Hedge Fund Activity: Q3 2020 in Review
16 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Nuvation Bio (NUVB) for Q3 2020, worth a combined $40.9M.
Buyers outnumbered sellers: 16 funds opened new NUVB positions and 0 closed out — a net gain of 16 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $8.64M.
- 16 institutional investors held Nuvation Bio (NUVB) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $40.9M of Nuvation Bio stock for Q3 2020.
- 16 funds opened new Nuvation Bio positions in Q3 2020 and 0 closed out, a net change of +16 holders.
- The largest Nuvation Bio buyer in Q3 2020 was Adage Capital Partners, an estimated $8.64M added.
Based on aggregated 13F filings for Q3 2020.